Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment

Guodong Li; Qi Huang; Vincent Kam Wai Wong; Wanhe Wang; Chung-Hang Leung

doi:10.1016/j.gendis.2023.01.034

您当前的位置：

首页 >

文章列表页 >

Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment

Rapid Communications | 更新时间：2024-02-04

- Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment
- Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment
- Genes & Diseases 2023年1卷第6期页码：2260-2262
- 作者机构：
  
  1. Institute of Chinese Medical Sciences and State Key Laboratory of Quality Research in Chinese Medicine, University of Macau,Macao SAR,China,999078
  2. Zhuhai UM Science and Technology Research Institute,Guangdong,Zhuhai,China,519000
  3. . Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology,Macao SAR,Dr,China,999078
  4. Institute of Medical Research, Northwestern Polytechnical University,Shaanxi,Xi'an,China,710072
  5. Macau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau,Macao SAR,China,999078
  6. Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau,Macao SAR,China,999078
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2023.01.034
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-11-1，
扫描看全文
Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment[J]. Genes & Diseases, 2023,1(6):2260-2262.

Guodong Li, Qi Huang, Vincent Kam Wai Wong, et al. Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment[J]. Genes & Diseases, 2023,1(6):2260-2262.
Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment[J]. Genes & Diseases, 2023,1(6):2260-2262. DOI： 10.1016/j.gendis.2023.01.034.

Guodong Li, Qi Huang, Vincent Kam Wai Wong, et al. Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment[J]. Genes & Diseases, 2023,1(6):2260-2262. DOI： 10.1016/j.gendis.2023.01.034.

摘要

Abstract

关键词

Keywords

references

1 G. Li, D. Li, C. Wu, et al.Homocysteine-targeting compounds as a new treatment strategy for diabetic wounds via inhibition of the histone methyltransferase SET7/9 Exp Mol Med, 54 (7) (2022), pp. 988-998

2 H.J. Zhong, W. Wang, W. Zhou, et al.Development of an orally bioavailable selective inhibitor of the menin-MLL Genes Dis, 10 (5) (2023), pp. 1735-1738

3 I. Bellón-Echeverría, J.P. Carralot, A.A. del Rosario, et al.MultiBacMam Bimolecular Fluorescence Complementation (BiFC) tool-kit identifies new small-molecule inhibitors of the CDK5-p25 protein-protein interaction (PPI) Sci Rep, 8(1) (2018), p. 5083

4 A. Pilling, S.H. Kim, C. HwangAndrogen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer Prostate, 82 (2) (2022), pp. 182-192

5 L. Gan, S. Chen, Y. Wang, et al.Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer Cancer Res, 69 (21) (2009), pp. 8386-8394

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据